Novan Inc. added its name to the IPO queue, revealing in an S-1 filing that it will seek to raise up to $60 million to advance its nitric oxide (NO) platform and programs in five dermatological conditions. The company plans to grant underwriters a 30-day option to purchase additional shares. Novan did not disclose the number of shares or price in its paperwork.